Our Global Impact
8000+ Truenat devices installed worldwide
Deployed in over 80 countries. Delivered over 25 million tests
In the year 2022, our parent company Molbio became the first Indian company in the MedTech space to become a unicorn. Our Truenat Real-Time PCR is the world’s first, and at present, only Point-of-Care platform approved by WHO for tuberculosis detection. It tests for over 25 diseases and is primarily focused on TB. In India, our platform also spearheaded India’s fight against COVID-19, conducting over 12 million tests.
Impact of our Innovations
Philippines
With only 28% of people infected with TB getting a WHO-recommended molecular test diagnosis, TB was rampant and underreported in the Philippines.
Impact:
- The introduction of Truenat resulted in a 316% rise in new TB case detection and a 14X increase in the screening of those with presumptive TB
- TB treatment success rate has also increased to 97% in 2023, with an average treatment success rate of 76%
Bangladesh
62,155 tests were carried out among 59,008 people in 2023 with signs and symptoms of TB. This resulted in the detection of TB in 4,446 (7.5%) individuals and rifampicin-resistant TB in 58 (1.3%) individuals.
Impact:
- There was a 20-fold increase in the proportion of newly diagnosed people with TB who were tested with a rapid molecular diagnostic (RMD) at the time of diagnosis
- An increase from 76.7% to 91.6% was observed in the proportion of newly diagnosed people with TB that were bacteriologically confirmed
India
India was the first country to implement Truenat, with approximately 1,600 instruments introduced in 2019 to support the national TB control program.
Impact:
- TB case detection has improved compared to smear microscopy
- 30% improvement in TB case notification rate in Andhra Pradesh
Kenya
Truenat machines were installed by The Ministry of Health’s National TB Program to strengthen TB diagnosis.
Impact:
- Improved bacteriological diagnosis. Of the 121 cases reported in 2022, 78% were bacteriologically and only 22% were clinically diagnosed
- 855 samples were tested on the Truenat platform, of which 64 were positive, and one multi-drug resistant TB. All the positives were put on treatment immediately
Democratic Republic of Congo
Truenat MTB Plus and MTB Rif Dx testing was implemented at 38 facilities in four provinces of DRC
Impact:
- The proportion of newly diagnosed people with TB tested with a rapid molecular test as an initial diagnostic increased significantly from 11.7% to 65.9%
- Similarly, the proportion of newly diagnosed people with TB that were bacteriologically confirmed also increased significantly from 54.9% to 66.8%
Uganda
38 Truenat Duo systems and reagents were deployed in Uganda with support from the Stop TB Partnership.
Impact:
- Saw a significant increase in the proportion of individuals with newly diagnosed TB who received a rapid molecular diagnostic (RMD) at project sites in Q4 2022 compared to Q4 2021
- A median percentage point increase of 26.7% (IQR 0.9- 67.2) was observed across all sites, with all but four sites showing a positive change
Tanzania and Mozambique
A TB Capt Study was conducted in Tanzania and Mozambique consisting of >4000 people
Impact:
- Truenat was able to detect more cases (7.3%) compared to detection rate in standard of care arm (4.8%)
- The 7 day treatment initiation rate was 98% in the intervention arm compared to 64% in the standard of care arm